This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Mecillinam for Treatment of Genital Chlamydia Infection (MecillinamCT)

This study has been terminated.
(Treatment failure on study medication observed)
More and Romsdal Health Trust
Information provided by (Responsible Party):
Anne Olaug Olsen, Oslo University Hospital Identifier:
First received: March 5, 2014
Last updated: June 18, 2015
Last verified: June 2015

The mainstay of treating both symptomatic and asymptomatic genital Chlamydia trachomatis infection has been macrolide antibiotics in the form of azithromycin, and alternatively tetracycline antibiotics in the form of doxycycline. Studies from the late nineties found a single dose of 1 g azithromycin to be equally effective as a 7 day course of 200 mg doxycycline a day. However, recent studies have reported increasing treatment failure that may indicate that resistance to macrolide antibiotics among Chlamydia trachomatis is evolving. Research regarding other bacterial species indicates a high frequency of mutation based resistance in conjunction with azithromycin use, i.e. when treating Mycoplasma genitalium infections. There has only been case reports of tetracycline resistance among human Chlamydia isolates, but a recent study suggest that there might be decreasing effectiveness also for doxycycline. Veterinaries has for several years observed increasing prevalence of tetracycline resistance among Chlamydia suis. Within the Chlamydia population there is promiscuous horizontal gene transfer.

If the current trend of declining cure rates continues, the investigators might face a situation where there are no documented and effective treatments for Chlamydia trachomatis infections. This underline an urgent need to expand the number of documented treatment options and mecillinam seems to be one of the options that warrant further investigation.

The objectives of this study is to prove the concept of treating genital Chlamydia trachomatis with mecillinam (Pivmecillinamhydrochlorid).

Condition Intervention Phase
Chlamydia Trachomatis Infection Chlamydial Urethritis Drug: Pivmecillinamhydrochlorid Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Mecillinam for Treatment of Genital Chlamydia Infection in Asymptomatic Men

Resource links provided by NLM:

Further study details as provided by Anne Olaug Olsen, Oslo University Hospital:

Primary Outcome Measures:
  • Negative control test for Chlamydia in urine (NAAT; Nucleic Acid AmplificationTest) [ Time Frame: 3 weeks after end of treatment ]

Enrollment: 20
Study Start Date: March 2014
Study Completion Date: May 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pivmecillinamhydrochlorid
Selexid 400 mg x 3 , 7 days
Drug: Pivmecillinamhydrochlorid
PO 400 mg x3 for 7 days
Other Name: Selexid


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Proficient in oral and written Norwegian
  • Positive NAAT in first void urine for Chlamydia trachomatis
  • Negative NAAT in first void urine for Mycoplasma genitalium
  • Heterosexual male
  • Asymptomatic

Exclusion Criteria:

  • Known allergies for mecillinam, penicillin or cephalosporines
  • Metabolic anomalies of aciduric type
  • Apparent underweight
  • Use of mecillinam within the last two months
  • Under treatment with Valproat, other anti-infective drugs, immuno-modulating medication
  • In the opinion of investigator,obvious reasons why patient will fails to adhere to treatment and follow-up protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02083276

Olafia Clinic,Oslo University Hosptial
Oslo, Norway
Sponsors and Collaborators
Oslo University Hospital
More and Romsdal Health Trust
Principal Investigator: Anne Olaug Olsen, MD, PhD Oslo UniversityHospital , Olafia Clinic
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Anne Olaug Olsen, MD PhD, Oslo University Hospital Identifier: NCT02083276     History of Changes
Other Study ID Numbers: 2013/1917
2013-002379-17 ( EudraCT Number )
Study First Received: March 5, 2014
Last Updated: June 18, 2015

Keywords provided by Anne Olaug Olsen, Oslo University Hospital:
Chlamydia trachomatis
Genital Diseases, Male

Additional relevant MeSH terms:
Communicable Diseases
Chlamydia Infections
Chlamydiaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Sexually Transmitted Diseases
Genital Diseases, Male
Genital Diseases, Female
Urethral Diseases
Urologic Diseases
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents processed this record on June 23, 2017